Bound Therapeutics
Business Services · Pennsylvania, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
3675 Market St Ste 200, Philadelphia, Pe...Website
www.boundtherapeutics.comRevenue
<$5 MillionIndustry
About Bound Therapeutics
Bound Therapeutics is a pioneering biotechnology firm focused on developing RNA-based therapies for rare and refractory diseases, particularly in oncology. Utilizing their proprietary Magic Bullet Designer platform, the company employs advanced AI and machine learning to enhance the precision and efficacy of RNA therapeutics. Currently in the preclinical stage, their pipeline includes innovative treatments for aggressive cancers and genetic disorders. Founded in 2015 by a team of experts, Bound Therapeutics aims to revolutionize cancer treatment and improve patient outcomes through targeted drug delivery.Explore more
Bound Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to Bound Therapeutics
Compare insights from companies similar to Bound Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Bound Therapeutics Tech Stack
A closer look at the technologies used by Bound Therapeutics
See more technologies
Top Business Services Companies
See more top companies
Frequently Asked Questions Regarding Bound Therapeutics
Sign Up For FreeTo access detailed company insights
Bound Therapeutics is a pioneering biotechnology firm focused on developing RNA-based therapies for rare and refractory diseases, particularly in oncology. Utilizing their proprietary Magic Bullet Designer platform, the company employs advanced AI and machine learning to enhance the precision and efficacy of RNA therapeutics. Currently in the precl... Read More
